BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Carteolol

A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

299+ PubMed studies analyzed · 52 RCTs · Evidence Score: 48.9

Research Domains

Carteolol has been studied across 20 research domains including 👁️ Vision & Eye, ❤️ Cardiovascular, 🔬 Inflammation, 🔬 Oncology, 🧠 Focus & Attention. The primary research focus is 👁️ Vision & Eye with 36% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Carteolol, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

levisoprenaline
3 shared targets
l
3 shared targets
l
3 shared targets
Bisoprolol
3 shared targets
Acebutolol
4 shared targets
tretoquinol
3 shared targets
Oxprenolol
3 shared targets
cgp
2 shared targets
Xamoterol
2 shared targets
Atenolol
4 shared targets
Loading evidence profile...

This evidence profile for Carteolol is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.